CONSTELLATION TECHNOLOGIES LIMITED — Capital/Financing Update 2011

Jan 23, 2011

==> picture [56 x 48] intentionally omitted <==

AGENIX LIMITED 爱健克斯有限公司

(ASX: AGX)

ABN 58 009 213 754 465 Auburn Road, Hawthorn East, Vic, 3123 Australia www.agenix.com

ASX MEDIA RELEASE

24 January 2011

Boardroom Radio Broadcast

Agenix Limited (ASX: AGX) ( Agenix ) provides current and prospective investors with the opportunity to listen to an audio broadcast of Nicholas Weston, Executive Chairman in a presentation titled "Agenix investor presentation and capital raising".

To listen , copy the following details into your web browser: brr.com.au/event/72857

The presentation details are as follows:

• Agenix investor presentation and capital raising

• Presented by Nicholas Weston, Executive Chairman

• Fri, 21 Jan 2011 2:00pm AEST

About Agenix Limited

Agenix is a publicly listed, Australian based international biotechnology company with a wholly owned subsidiary in China. The company has two core businesses:

• In Innovative Biopharmaceuticals, Agenix has ‘in principal’ rights to clinically develop a pipeline of innovative and proprietary Hepatitis B therapies for commercialisation in China. Through its wholly owned subsidiary, Agenix Biopharmaceutical (Shanghai), established in 2007, the company has established a collaboration with the Institute of Medicinal Biotechnology ( IMB ) of the Chinese Academy of Medical Sciences in Beijing to develop and commercialise AGX-1009, a next-generation, patented prodrug analog of an existing compound for the treatment of chronic Hepatitis B in China.

• In Medical Diagnostics , the company’s lead indicator is a patented monoclonal antibody diagnostic called Thromboview® that, uniquely, detects live blood clots (DVT and PE) in the human body. ThromboView® has successfully completed two FDA Phase II human clinical trials in the United States. The company is positioning Thromboview® as an innovative diagnostic (a ‘theranostic’) to support the use of Novel Oral Anti-Coagulants and is seeking a development partner in China to commercialise the indicator.

ASX Media Release Page: 2 Date: 23 December 2010

==> picture [41 x 36] intentionally omitted <==

Agenix has been listed on the Australian Securities Exchange (ASX: AGX) since 1987. Agenix is active in China, and seeking to establish commercial partnerships in the rest of the world. For additional information on Agenix Limited, please visit the company’s website at agenix.com

Yours faithfully,

==> picture [159 x 46] intentionally omitted <==

Nicholas Weston Executive Chairman Enclosures: Nil

CONTACT: Company Secretary Jeffrey Luckins : +61 3 9822 8686 or email jluckins@agenix.com